| High-income North America |
| Prevalence |
152 623 (118137–187434) |
290 067 (216 569–380 633) |
325 847 (245 317–433 303) |
332 019 (260 911–415 580) |
1 114 609 (893 445–1 366 118) |
| Cases per 100 000 |
888 (687–1090) |
1290 (963–1693) |
1385 (1042–1841) |
1409 (1107–1764) |
1224 (981–1501) |
| YLD |
6825 (4491–9800) |
12 497 (7946–18 913) |
13 922 (9109–20 643) |
14080 (9443–20 526) |
48069 (31 567–70 783) |
| Rate per 100 000 |
40 (26–57) |
56 (35–84) |
59 (39–88) |
60 (40–87) |
53 (35–78) |
| Western Europe |
| Prevalence |
276 367 (198 687–374997) |
517 470 (353 529–726 275) |
525 529 (358 367–760 147) |
518 419 (371 643–710 943) |
1 863 897 (1 406 494–2 458 616) |
| Cases per 100 000 |
1556 (11 19–211 1) |
2200 (1503–3088) |
2261 (1542–3271) |
2211 (1585–3031) |
2020 (1524–2664) |
| YLD |
12 670 (8363–18 679) |
22 999 (14 561–35 761) |
23 903 (15 661 –36 263) |
24 246 (16 137–35 060) |
85 277 (56 719–126 152) |
| Rate per 100 000 |
71 (47–105) |
98 (62–152) |
103 (67–156) |
103 (69–149) |
92 (61–137) |
| Central Europe, Eastern Europe, and Central Asia |
| Prevalence |
564 728 (440 263–703 012) |
941 642 (717 458–1 223 861) |
868 204 (677 153–1 113574) |
846 765 (688 153–1 039 601) |
3 283 489 (2 696 872–3 979 988) |
| Cases per 100 000 |
2490 (1941–3100) |
3424 (2609–4450) |
3605 (2812–4624) |
3709 (3014–4553) |
3206 (2633–3886) |
| YLD |
23 331 (15 339–33908) |
37 060 (23 671–57 112) |
33 650 (22 175–50 785) |
32 090 (21 729–46 690) |
129096 (86 179–190 154) |
| Rate per 100 000 |
103 (68–150) |
135 (86–208) |
140 (92–211) |
141 (95–204) |
126 (84–186) |
| Latin America and the Caribbean |
| Prevalence |
740 115 (608 175–891 456) |
1 382 342 (1 139 624–1 686 144) |
1 722 148 (1 458 855–2 078 414) |
2 134 390 (1 864 828–2 454466) |
6 060 394 (5 274074–6 953 437) |
| Cases per 100 000 |
1820 (1495–2192) |
2795 (2305–3410) |
3495 (2961–4218) |
4273 (3733–4914) |
3037 (2643–3484) |
| YLD |
35 105 (24 358–49 102) |
56 438 (38 220–82 876) |
63 224 (43 422–93 124) |
71 838 (49 073–102 168) |
231 800 (161 066–330 075) |
| Rate per 100 000 |
86 (60–121) |
114 (77–168) |
128 (88–189) |
144 (98–205) |
116 (81 –165) |
| Southeast Asia, East Asia, and Oceania |
| Prevalence |
2 249 931 (1 808000–2 713 770) |
3 932 438 (3 111 842–4917097) |
4413 990 (3 605469–5 471 494) |
4 703 742 (4018 023–5 517 485) |
15 585 040 (13 235 355–18 269 625) |
| Cases per 100 000 |
2024 (1627–2442) |
2914 (2306–3644) |
3236 (2644–4012) |
3379 (2887–3964) |
2823 (2397–3309) |
| YLD |
109 196 (76 200–153 579) |
166 445 (111 487–245 186) |
176 644 (121 421–254986) |
181 132 (126 902–254 871) |
653 115 (455 897–924467) |
| Rate per 100 000 |
98 (69–138) |
123 (83–182) |
130 (89–187) |
130 (91–183) |
118 (83–167) |
| South Asia |
| Prevalence |
3 774616 (3 077 028–4508 330) |
6 439 687 (5 251 987–7 862 31 1) |
7 183 140 (6 119 227–8 571 685) |
8 143 890 (7 174906–9 255 169) |
26 038 313 (22 730 901–29 883 169) |
| Cases per 100 000 |
2675 (2181–3195) |
3595 (2932–4389) |
4039 (3441–4820) |
4577 (4032–5201) |
3671 (3205–4213) |
| YLD |
165 553 (113090–235 319) |
245 087 (163 525–364047) |
249 088 (168 740–368 544) |
261 408 (181 428–376 079) |
948 988 (648 070–1 367 226) |
| Rate per 100 000 |
117 (80–167) |
137 (91–203) |
140 (95–207) |
147 (102–211) |
134 (91–193) |
| Sub-Saharan Africa |
| Prevalence |
2 648 821 (2 192 343–3 177 168) |
4 543 637 (3 814 398–5 446 542) |
4907 105 (4 263 876–5 738 216) |
4973 223 (4439 848–5 562 714) |
17 405 890 (15 387972–19 716012) |
| Cases per 100 000 |
2055 (1700–2464) |
3081 (2587–3693) |
3761 (3268–4398) |
4496 (4014–5029) |
3154 (2788–3572) |
| YLD |
129 586 (91 767–177 285) |
178 202 (122 692–257 198) |
172 247 (1 19 122–245 839) |
161 966 (113 190–226 755) |
667 326 (471 998–937 436) |
| Rate per 100000 |
101 (71–138) |
121 (83–174) |
132 (91 –188) |
146 (102–205) |
121 (86–170) |
| North Africa and the Middle East |
| Prevalence |
1 270 261 (1 006 150–1 584 554) |
2 128 785 (1 665 430–2 721 426) |
2 186 398 (1 774129–2 745 766) |
2 218 003 (1 877 690–2 634071) |
7 960 528 (6 721 789–9 429 083) |
| Cases per 100 000 |
2462 (1950–3071) |
3446 (2696–4405) |
3864 (3136–4853) |
4224 (3576–5017) |
3384 (2858–4009) |
| YLD |
56 999 (38 277–81 141) |
82 725 (53 508–125 192) |
79 230 (53 191–119 232) |
76 351 (52 324–1 10 075) |
304 847 (206 858–442 931) |
| Rate per 100 000 |
110 (74–157) |
134 (87–203) |
140 (94–211) |
145 (100–210) |
130 (88–188) |
| Global |
| Prevalence |
11 902 507 (9 685 418–14 340 209) |
20584553 (16 619 635–25 501 975) |
22 554407 (18 878 363–27 433 881) |
24339696 (21 124978–28 083 187) |
80 857 974 (69 402 207–94059 458) |
| Cases per 100 000 |
2193 (1785–2642) |
3113 (2514–3857) |
3545 (2967–4312) |
3948 (3427–4556) |
3116 (2675–3625) |
| YLD |
549 006 (378 690–770 472) |
818 335 (546 869–1 207 657) |
829363 (566 152–1 214034) |
842 676 (582 361–1 198 086) |
3 133 280 (2 171 484–4467 090) |
| Rate per 100 000 |
101 (70–142) |
124 (83–183) |
130 (89–191) |
137 (94–194) |
121 (84–172) |
